Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The investment bank says funding was down 57% last month, to $2.7 billion, and argues the new administration’s FDA ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.